BridgeBio Pharma ($BBIO) Insider Trading & Smart Money Activity
BridgeBio Pharma, Inc. ($BBIO) has 20 insider trades, 2 congress trades, 10 13F position changes and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 3 insiders sold ($3.59M), net -$3.59M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 3
- Net insider $ (12 mo)
- -$3.59M
- Congress trades (12 mo)
- 2
- 13F moves on file
- 10
- Analyst ratings on file
- 2
BBIO insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 3 · $2.90M | 1 / 0 | 4 / 6 |
| Q3 2026 | 0 | 1 · $690.85K | 0 / 1 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All BBIO insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | Barclays | Reiterates to Overweight | PT $156 | -2.3% | — | ||||||
| Congress | Gilbert Ray Cisneros Jr. | Sale | $1,001 - $15,000 | +1.5% | Read | ||||||
| Insider | Kumar NeilChief Executive Officer | Sell (Open-market sale) 10b5-1 | 10K sh | $690.85K | -1.5% | — | |||||
| Insider | Jennifer Cook | Sell (Open-market sale) 10b5-1 | 37.17K sh | $2.60M | +7.4% | +21.1% | — | ||||
| Insider | Jennifer Cook | Buy (Option exercise) | 37.17K sh | $456.55K | +7.4% | +21.1% | — | ||||
| Insider | Hannah Valantine | Sell (Open-market sale) 10b5-1 | 2.20K sh | $150.58K | +8.5% | +20.8% | — | ||||
| Insider | Jennifer Cook | Sell (Open-market sale) 10b5-1 | 2.20K sh | $150.58K | +8.5% | +20.8% | — | ||||
| Insider | Hannah Valantine | Sell (Option exercise) | 2.81K sh | +4.5% | +19.9% | Read | |||||
| Insider | Hannah Valantine | Buy (Option exercise) | 2.81K sh | $117.18K | +4.5% | +19.9% | — | ||||
| Insider | Ali Satvat | Buy (Grant or award) | 3.99K sh | +4.5% | +19.9% | — | |||||
| Insider | James Momtazee | Buy (Grant or award) | 5.28K sh | +4.5% | +19.9% | — | |||||
| Insider | Frank Mccormick | Buy (Grant or award) | 3.99K sh | +4.5% | +19.9% | — | |||||
| Insider | Andrew Lo | Buy (Grant or award) | 3.99K sh | +4.5% | +19.9% | — | |||||
| Insider | Charles Homcy | Buy (Grant or award) | 5.28K sh | +4.5% | +19.9% | — | |||||
| Insider | Fred Hassan | Buy (Grant or award) | 3.99K sh | +4.5% | +19.9% | — | |||||
| Insider | Andrea Ellis | Buy (Grant or award) | 3.99K sh | +4.5% | +19.9% | — | |||||
| Insider | Ronald Daniels | Buy (Grant or award) | 3.99K sh | +4.5% | +19.9% | — | |||||
| Insider | Douglas Dachille | Buy (Grant or award) | 3.99K sh | +4.5% | +19.9% | Read | |||||
| Insider | Jennifer Cook | Buy (Grant or award) | 5.28K sh | +4.5% | +19.9% | — | |||||
| Insider | Eric Aguiar | Buy (Grant or award) | 5.28K sh | +4.5% | +19.9% | — | |||||
| Insider | Charles Homcy | Sell (Tax withholding) | 788 sh | $52.22K | +4.5% | +17.2% | — | ||||
| Analyst | Mizuho | Reiterates to buy | PT $96 | +3.0% | +20.5% | Read | |||||
| Insider | Jennifer Cook | Sell (Option exercise) | 83.09K sh | +1.4% | +21.6% | — | |||||
| 13F | Viking Global Investors | Reduced | -2.55M sh | $882.02M | +4.5% | +2.8% | — | ||||
| 13F | Two Sigma Advisers | Sold out | -1.40M sh | +4.5% | +2.8% | — | |||||
| 13F | Nomura Asset Management International | Reduced | -190.53K sh | $114.31M | +4.5% | +2.8% | Read | ||||
| 13F | Janus Henderson Group | Added | +2.18M sh | $981.57M | +4.5% | +2.8% | — | ||||
| 13F | Janus Henderson Group | Added | +2.18M sh | $884.84M | +4.5% | +2.8% | Read | ||||
| 13F | Farallon Capital Management | Added | +367K sh | $697.54M | +4.5% | +2.8% | — | ||||
| 13F | Brevan Howard Capital Management | Reduced | -91.95K sh | $6.08M | +4.5% | +2.8% | Read | ||||
| 13F | Alliancebernstein L.P. | Reduced | -141.84K sh | $142.18M | +4.5% | +2.8% | — | ||||
| 13F | Alliancebernstein L.P. | Reduced | -141.84K sh | $128.16M | +4.5% | +2.8% | Read | ||||
| 13F | Gw&K Investment Management | Added | +336.52K sh | $71.70M | -0.6% | -2.6% | — | ||||
| Congress | Gilbert Cisneros | Purchase | $1,001 - $15,000 | +1.0% | +4.2% | Read |
1W / 1M / 6M = how BBIO moved from the trade or filing date.
Insider trading in BBIO: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer | 1 | -$690.85K | Sep 17, 2026 | |
| Jennifer Cook | 5 | -$2.75M | Jun 24, 2026 | ||
| Hannah Valantine | 3 | -$150.58K | Jun 23, 2026 | ||
| Charles Homcy | 2 | — | Jun 22, 2026 | ||
| Ali Satvat | 1 | — | Jun 22, 2026 | ||
| James Momtazee | 1 | — | Jun 22, 2026 | ||
| Frank Mccormick | 1 | — | Jun 22, 2026 | ||
| Andrew Lo | 1 | — | Jun 22, 2026 | ||
| Fred Hassan | 1 | — | Jun 22, 2026 | ||
| Andrea Ellis | 1 | — | Jun 22, 2026 | ||
| Ronald Daniels | 1 | — | Jun 22, 2026 | ||
| Douglas Dachille | 1 | — | Jun 22, 2026 | ||
| Eric Aguiar | 1 | — | Jun 22, 2026 |
Members of Congress trading BBIO
Institutions moving BBIO (13F)
Analyst ratings on BBIO
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Barclays | Reiterates | Overweight | $157 → $156 | -2.3% | — | |||
| Mizuho | Reiterates | buy | $96 | +3.0% | +20.5% | Read |
Frequently asked questions
Are BBIO insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 3 insiders made 4 open-market sales worth $3.59M, a net -$3.59M.
What is the latest insider trade in BBIO?
Kumar Neil, Chief Executive Officer filed a sell (open-market sale) of 10K sh worth $690.85K on Sep 17, 2026.
Which members of Congress traded BBIO?
2 disclosed trades by Gilbert Ray Cisneros Jr. and Gilbert Cisneros. The latest was on Sep 29, 2026.
Which institutions changed their BBIO positions?
Recent 13F filers moving the stock include Janus Henderson Group, Alliancebernstein L.P., Viking Global Investors, Two Sigma Advisers and Nomura Asset Management International.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.